Investment Institute
Bringing together experts from across our research and investment teams to help you make more informed investment decisions.
AXA IM's Investment Institute
The age of AI and its long-term investment potential
Technology stocks are dominating equity markets once again chiefly because of the recent rise, and long-term potential, of artificial intelligence
READ THE ARTICLETrending topics
What's on investors' minds
Radical transparency: Does more data add up to greater climate progress?
More than 80% of the world economy aims to be net zero by 2050. Such commitment requires significant action, and the investment world is no exception. But with many studies showing that greenwashing, a lack of common language and data are standing in the way, we ask: is more transparency always a good thing? Does more data add up to greater climate progress? Our host, Herschel Pant, speaks to Nigel Topping, Policy Adviser and former UN Climate Change High-Level Climate Champion, and Hans Stoter, Global Head of AXA IM Core, as well as Justin Travlos, Head of Responsible Investment, AXA IM Alts.
Listen to our podcasts
Macroeconomics
Read our latest views on global macroeconomic events.
Take Two: ECB raises interest rates to record high; US inflation rises more than expected
- by
- 18 September 2023 (3 min read)
Asset Class Views
Read our latest thinking on asset classes.
Lettuces and Prime Ministers (not cabbages and kings)
- by
- 15 September 2023 (7 min read)
Sustainability
We believe sustainable investing is key to long-term financial returns.
Why living wages should be considered a driver of human capital value, not a cost
- by
- 06 September 2023 (7 min read)
AGM season 2023: New challenges highlight the achievements of responsible investors
- by
- 07 August 2023 (7 min read)
Four critical elements for asset managers to meet the biodiversity challenge
- by
- 01 August 2023 (7 min read)
Future Trends
Our latest thinking on the megatrends changing the way we work, live and invest.
Game-changing Alzheimer’s drugs could drive a wave of investment across biotech
- by
- 14 September 2023 (7 min read)
Disclaimer
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.